ONO PHARMACEUTICAL CO., LTD. 
By
Corporate Communications
Phone: +81-6-6263-5670
May 15, 2012
Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced today
that Ono and Scil Proteins GmbH (Halle, Germany) signed a
collaboration agreement for joint discovery and development
of new protein therapeutics. Under the terms of the
agreement, Ono will pay to Scil Proteins research funding,
and make milestone payments for research, development and
commercialization, and royalty payments based on sales.
Scil Proteins will identify unique proteins that bind certain
target molecule(s) provided by Ono taking advantage of its
proprietary Affilin® drug discovery platform.
Ono will further evaluate biological activities and safety
profiles of selected proteins and discover new protein-based
drug candidates. Ono will have worldwide exclusive rights to
develop and commercialize any
pharmaceutical product containing a protein developed through
this collaboration.
"This collaboration with Ono is an important commercial
milestone for Scil Proteins, which further affirms the
technical and scientific concepts behind our
Affilin® platform", commented Henning
Afflerbach, Scil Proteins' CBO. "We are pleased to have
successfully implemented our fully integrated offering of
providing proprietary, fully patent-protected compounds in
combination with
production process development and GMP manufacturing into a
cutting-edge collaborative research with a leading
pharmaceutical company. Ono established outstanding
scientific and developmental expertise."
Kazuhito Kawabata, Ph.D., Member of the Board of Directors,
Executive Officer and Executive Director, Discovery and
Research of Ono said: "We strongly believe that Scil Proteins
is the partner of choice to identify proteins binding the
target molecules we chose. We are pleased to be working
together and look forward to creating innovative drugs for
unmet medical needs."
- Ends -
Scil Proteins is a biopharmaceutical company discovering and
developing Affilin® molecules and working with
industry partners in the development and manufacture of
protein therapeutics and diagnostics. Scil Proteins has built
a pipeline of Affilin® therapeutics targeting
cancer. In addition, the Company has a longstanding expertise
in protein production and process development and, therefore,
offers GMP contract biomanufacturing to its clients in the
biotech and pharma industries.
With state-of-the-art equipment and a particular expertise in
refolding proteins, the Company has an excellent track record
in supplying top level support for its partners. Scil
Proteins has supported a number of different companies such
as Roche, Actavis and Lundbeck in process development and
manufacturing of recombinant protein drugs. Scil Proteins is
a well-established private company located in Halle, Germany.
To learn more about Scil Proteins, please visit www.scilproteins.com.
About Affilin®
Scil Proteins' proprietary Affilin® platform
allows the generation of innovative biopharmaceuticals.
Affilin® molecules are ubiquitin-based proteins
that bind targets with high affinity, specificity, heat
stability, and little immunogenicity, which are highly
important features as therapeutics.
|
distributed by
|
